Prevention of Restenosis After Percutaneous
Transluminal Coronary Angioplasty With Thromboxane A2-Receptor Blockade
Although major improvements in angioplasty techniques have resulted in a high initial success rate, the late restenosis rate of 20-40% still limits the longterm benefit of the procedure.1-5 For multivessel angioplasty, the restenosis percentage is even higher. 6 It is well known that restenosis after balloon angioplasty is a time-related phenomenon, occurring in the first months after balloon angioplasty.5,7 Only very rarely does restenosis present itself more than 6 months after coronary angioplasty8,9; therefore, the follow-up period has been limited to the first six months after angioplasty in the current trial. Deendothelialization and vascular disruption at the angioplasty site expose vessel wall smooth muscle cells and collagen directly to blood. This causes platelet adhesion, platelet aggregation, and activation of the clotting cascade. In addition, platelets may also activate leukocytes to release vasoconstrictor leukotrienes. These effects appear to be thromboxane mediated as inhibition of thromboxane reduces leukocyte activation.10 Adhesion and aggregation of platelets at the postangioplasty plaque can lead to an early occlusion within the first 48 hours after angioplasty. Over the long term, platelet-and monocytederived growth factors stimulate smooth muscle cell proliferation, leading to the fibroproliferative reaction of the vessel wall in the first months after balloon angioplasty.11-13 Apart from the proliferation process, organization of mural thrombi may also be the cause of restenosis.1415 Early platelet aggregation thus appears to play a pivotal role in the occurrence of postangioplasty thrombotic occlusion and the restenosis process. 16 Thromboxane A2 (TXA2) is a potent platelet aggregational agent and vasoconstrictor released from activated platelets. Beyond the platelet-activating effect, TXA2 also appears to have a more direct effect on vascular smooth muscle cell proliferation. Using primary cultures of smooth muscle from rat aorta, Hanasaki et al17 demonstrated a mitogenic effect of thromboxane on smooth muscle cells, which occurs through binding to its specific receptor and may be suppressed by thromboxane-receptor blockade,17 a promising approach to the inhibition of the effects of TXA2.18 TXA2-receptor blockade prevents the deleterious actions of TXA2 while sparing the beneficial synthesis of prostacyclin. GR32191B has been shown to be a potent and specific TXA2-receptor-blocking drug that antagonizes the proaggregatory, vasoconstrictor, and bronchoconstrictor actions of TXA2, as well as those of agents that act indirectly via TXA2, such as collagen and arachidonic acid, and agents that directly stimulate the receptor, such as prostaglandin H2 and the TXA2 mimetic U-46619. 18, 19 Although not affecting platelet adhesion, it potently inhibits the aggregation of platelets onto damaged blood vessels. 18, 20 This property, together with the ability of the compound to inhibit the platelet-release reaction, indicates a potential clinical use of GR32191B in reducing early thrombotic events, late intimal hyperplasia, and subsequent restenosis after coronary angioplasty. The present multicenter, randomized, double-blind, placebo-controlled trial (Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism [CARPORT]) was carried out to evaluate the role of GR32191B in the prevention of late restenosis after PTCA.
Methods
All patients with angina and angiographically proven coronary artery disease who were scheduled for angioplasty were considered for inclusion at one of six participating centers (see "Appendix"). The trial was carried out according to the declaration of Helsinki, and specific exclusion criteria are given in Table 1 . A screening log was maintained in' two centers. At these two centers, 1,614 patients were screened from December 1987 through June 1989, and 72% were excluded (Table 1) . Randomization and Treatment Protocol Randomized, double-blind trial medication was allocated by telephone after the patient had been registered at the central allocation service. Trial medication consisted of either GR32191B for 6 months or control treatment with one dose of aspirin, followed by matching placebo.
One hour before angioplasty, patients allocated to GR32191B received 4 tablets of 20 mg GR32191B orally and an intravenous injection of a physiological salt solution. Patients allocated to control treatment received 250 mg i.v. acetylsalicylic acid and 4 placebo tablets. In addition to trial medication, all patients received a bolus of 10,000 units i.v. heparin at the beginning of the procedure. After two hours, 5,000 units/hr was given for as long as the procedure continued. Also, all patients received 10 mg nifedipine every 2 hours for the first 12 hours and 20 mg slow-release nifedipine tablets thereafter every 8 hours up to the second day after angioplasty.
In those patients in whom angioplasty was successful, either 40 mg GR32191B twice daily or placebo was started in the evening and continued until the end of follow-up. The final dose of trial medication was taken 1 hour before the follow-up angiogram. In addition, all participants were provided with paracetamol in 500-mg tablets for use as analgesic and were asked to avoid acetylsalicylic acid or nonsteroidal anti-inflammatory drugs while on trial medication. centers (Rotterdam), platelet aggregation tests, using ADP and U-46619 (a TXA2 mimetic) as aggregants, were carried out to assess pharmacological activity of the drug. At 6-month follow-up, 1-4 days before angiography, a symptom-limited exercise test was performed on a bicycle ergometer according to two different protocols. In Berlin, the test was performed with the patient in a supine position, starting with a work load of 25 W, which increased by 25 W every 2 minutes. In the other clinics, the test was performed with the patient in a sitting position, starting with a work load of 20 W, which was increased by 20 W every 1 minute. Exercise was continued until anginal symptoms, a drop in systolic blood pressure, severe arrhythmia, or a ST depression of more than 1 mm occurred. A 12-lead electrocardiogram was recorded during exercise and recovery. ST changes were measured 80 msec after the J point. Horizontal or downsloping ST segment depression associated with anginal symptoms was considered a positive response to the stress test. The follow-up coronary angiogram was performed at the 6-month visit. If symptoms recurred within 6 months, coronary angiography was carried out earlier. If no definite restenosis was present and the follow-up time was less than 4 months, the patient was asked to undergo another coronary arteriogram at 6 months.
Quantitative Angiography
All cineangiograms were analyzed using the CAAS system, which has been described in detail.24-26 A computer-derived reconstruction of the original arterial dimension at the site of obstruction (assuming there is no disease present) is used to define the interpolated reference diameter. The absolute values of the stenosis diameter as well as the reference diameter are measured by the computer using the known contrast catheter diameter as a scaling device. Because the algorithm is not able to measure total occlusions, a value of 0 mm was substituted for the minimal lumen diameter and 100% for the percent diameter stenosis. In these cases, the postangioplasty reference diameter was substituted for the reference diameter before angioplasty. In contrast, for a totally occluded vessel at follow-up angiography, a value was not substituted, so that the change in reference diameter from after angioplasty to follow-up was only calculated when an actual measurement was available.
Balloon-to-artery ratio was defined as the ratio of the mean balloon diameter measured in a single nonforeshortened projection and the reference diameter of the dilated segment in the same projection. Assay of GR32191B and Platelet Aggregation Tests Plasma samples of patients allocated to active drug treatment were taken before first drug intake and approximately 1 hour afterward. These samples were analyzed for GR32191B by high-performance liquid chromatography with fluorescence detection after solid-phase extraction on an advanced automated sample processor.
For the aggregation tests, blood was drawn from the patient by venipuncture. Nine parts of blood were mixed with 1 part 0.13 M sodium citrate solution. The blood was then centrifuged (15 minutes at 200g at room temperature), and the supernatant plateletrich plasma (PRP) was carefully removed using a plastic Pasteur pipette and transferred to a separate plastic tube. The remaining blood was centrifuged for 10 minutes at 2,000g at room temperature to obtain platelet-poor plasma (PPP). PPP was then added to PRP to obtain PRP with a platelet count of 200 x 109 platelets/l. The PRP was stored at room temperature in full, capped tubes (contents, 5 ml) for 30-90 minutes. Aggregation was performed in a Payton twin-channel aggregometer at 37°C with a stirring speed of 900 rpm. Maximum and minimum light transmission was set up using PPP and PRP, respectively. Samples of 400 ,ul PRP were incubated in the aggregometer for 3 minutes at 37°C, and 40 ,ul of either the TXA2 mimetic U-46619 (final concentration, 1 gM) or ADP (final concentration, 10 ,M) was added. Aggregation was allowed to proceed to its maximum or a period of 5 minutes was allowed, whichever was longer. Aggregation was expressed as the peak response and represented in millimeters.
End Points
The primary end point of the present study was the within-patient change in minimal lumen diameter as determined by quantitative angiography after PTCA and at follow-up. Post-PTCA values were obtained from the last post-PTCA angiogram made before withdrawal of the guide catheter. The initial procedure were considered finished when the guide catheter was removed. In case evolution of the clinical condition required repeat PTCA (with reinsertion of guide catheter), the angiogram made before repeat balloon inflations was used to obtain follow-up values, regardless of the timing of repeat PTCA (hours, days, or weeks). Otherwise, the follow-up angiogram made according to protocol was used. For each dilated segment, the post-PTCA and follow-up minimal lumen diameters were taken as the mean values from multiple matched projections. Within-patient change (i.e., the primary end point) was defined as the follow-up minus the post-PTCA value. In case more than one segment was dilated (multivessel or multisite procedures), the change in minimal luminal diameter per patient was calculated as the average of the different lesions. Secondary end points were clinical events believed to be related to restenosis. These were death (regardless of cause), nonfatal myocardial infarction (at least two of the following: typical pain, electrocardiographic changes suggesting acute myocardial infarction, cardiac enzymes more than twice the upper limit of normal), coronary artery bypass graft surgery (CABG), and repeat angioplasty at the same site. Events were classified as "procedural" (i.e., onset of event or decision to perform another procedure taken while the guide catheter was still in place), "early" (i.e., onset within 24 hours of guide catheter removal), or "late" (i.e., onset more than 24 hours after guide catheter removal). Another secondary end point was the presence and severity of angina pectoris as assessed by the Canadian Cardiovascular Society classification at last follow-up.
Statistical Methods and Analysis
The minimal sample size was estimated at the outset of the study to be 233 patients in each group on the assumption of a change of -0.40+0.50 mm in mean minimal lumen diameter between postangioplasty and follow-up angiogram in the control group5 and -0.25+50 mm (i.e., a 30% difference) in the active drug group (two-sided test with an a error of 0.05 and a power of 0.90).
In the comparison between treatment groups for the primary angiographic end point, patients included were those who had a successful initial angioplasty, had a quantitatively analyzable PTCA angiogram, had follow-up angiogram made while on trial medication, and were compliant with trial medication (had used at least 80% of their trial medication during the intervening period and had not discontin- ued trial medication for more than 3 days). To test the null hypothesis that both mean changes in minimal lumen diameter are equal, an unpaired t test was used and a 95% confidence interval for the effect measure was obtained.
Comparisons for each clinical event were made on the basis of intention to treat (i.e., with inclusion of all patients who were randomized-defined as having taken at least their initial oral dose of trial medication -and regardless of angioplasty outcome or trial medication compliance). Also, the clinical status of each patient at the end of follow-up was ranked by assignment to the lowest applicable category of the following ordinal scale: 1, death; 2, nonfatal myocardial infarction; 3, status after CABG; 4, status after repeat PTCA; 5, presence of angina pectoris (Canadian Cardiovascular Society classification of 1 or higher); and 6, none of the above. The percentages of patients in each of these categories were compared between treatment groups on the basis of intention to treat. For all comparisons, the null hypothesis of no difference was tested by appropriate statistical tests.
Results
A total of 707 patients were randomized. Of these patients, 353 were randomized to receive GR32191B, and 354 were randomized to the control group. Selected demographic, clinical, and angiographic characteristics of the two study groups are shown in Tables 2 and 3 . No baseline differences were observed between the two groups. Figure 1 shows the patient flow and the reasons that subjects could not be evaluated with respect to quantitative angiographic restenosis. In 10 patients, angioplasty was not performed. One patient, who could not be treated because of radiographic equipment failure, was rerandomized 2 weeks later and retrospectively excluded as a protocol violator (previous participation in the trial was an exclusion criterion). Angioplasty (Figure 1 ). Table 4 and Figure 2 summarize the quantitative angiographic findings of the efficacy analysis. At follow-up, the loss of minimal lumen diameter was identical in both groups: -0.31 mm (treatment effect, 0 mm; 95% confidence intervals, -0.09, 0.09). Figure   3 is a cumulative curve of the change in minimal lumen diameter observed in both groups. A loss of 0.72 mm or more5,27 corresponds to restenosis rates of 19% in the control group and 21% in the treated group. Therefore, the relative risk for restenosis in the treated group with respect to the control group is 1.15 (95% confidence intervals, 0.82, 1.60).
Result ofAngiographic Efficacy Analysis

Results of Bicycle Ergometry
Of 649 patient who had a successful angioplasty, 539 underwent exercise testing at follow-up. Reasons for not performing the test were death (2 patients), unstable angina (45 patients), inability to perform the Clinical Follow-up Table 6 shows the total number of events during 6- treated group and 197 (56%) in the control group were event and symptom free at 6-month follow-up.
Results of GR32191B Assay and Platelet Aggregation Tests
In four of the six participating centers, GR32191B plasma levels for patients allocated to the GR32191B group were analyzed before first drug intake and approximately 1 hour after first drug dose. GR32191B was not detected above the limit of quantification in the predose samples but was present in the postdose samples at concentrations ranging from 5 to 1,210 ng/ml, with a mean of 392±241 ng/ml, indicating that GR32191B was absorbed into the circulation after the oral administration of GR32191B.
During each follow-up visit of the Rotterdam patients, platelet aggregation tests were carried out using the TXA2 mimetic U-46619 and ADP as aggregants. During the first three visits (3 weeks, 3 months, and 6 months after angioplasty), patients were on trial medication. The fourth visit (7 months after angioplasty) served as a control measurement. A total of 162 patients were tested at least one time during follow-up ( 
Bleeding Complications and Tolerability
Only mild bleeding events occurred in the trial. In-hospital bleeding events occurred in 18 patients (5%) in the control group and 15 patients (4%) in the treatment group (hematoma at puncture site of more than 5 cm, 14 versus 12 patients; prolonged bleeding at puncture site, three versus four; hematoma elsewhere, one versus none). During follow-up, four hematomas were reported in the control group and five in the treatment group. No cerebral bleeding or cerebral thrombotic events were encountered during the time course of the trial. Generally, the drug was well tolerated, and reported side effects were mild and evenly distributed in the two treatment groups. Total reported side effects were 40 in the control group and 44 in the treatment group (epigastric discomfort, 19 versus 20 patients; rash, 11 versus 12; nausea, six versus three; salivation, none versus two; headache, three versus six; fever, one versus one). The reappearance of angina as a sole criterion of restenosis underestimates the angiographic rate of restenosis, and the value of recurrent anginal symptoms as a marker of restenosis is difficult to assess in many studies because the timing and completeness of angiographic follow-up often have been determined by symptomatic status. 39 In the present trial, repeat catheterization with quantitative angiography was obtained in 88.5% of 649 patients with a successful angioplasty. A majority of patients (354 of 522, or 68%) were recatheterized in the 6-month (+2 weeks) time interval. The remaining patients underwent early recatheterization because of clinical suspicion for restenosis. Of the 522 compliant patients who had angiography at follow-up, 345 were angina free and 165 were symptomatic at follow-up. As shown in Figure 4B , there was considerable overlap between the change in minimal lumen diameter of patients with and of those without angina at follow-up angiography. This underscores that reappearance of angina is a poor proxy to the anatomic substrate at issue and confirms the poor predictive value of symptoms found in other studies,39 which may be explained by the presence of other mechanisms for angina, such as incomplete revascularization or progression of disease in other vessels.
Several studies have examined the usefulness of ergometry to detect restenosis after angioplasty.39 These studies have generally found that the presence of exercise-induced angina, ST segment depression, or both is not highly predictive of restenosis whether the test is performed early or late after angioplasty.39 Figure 4B illustrates this for our data in a similar fashion as for angina. In view of the above, quantitative coronary angiography has emerged as the most reliable method for judging late results.
In studies evaluating the biology of restenosis, a continuous measure of the degree of lumen obstruction is preferable because any progression of the stenosis reflects the process of interest regardless of whether an arbitrarily defined threshold of obstruction is reached. Keeping in mind that an angio- First, it could be hypothesized that the absence of benefit was due to poor absorption. In four participating clinics, plasma levels of GR32191B before first drug dose and 1 hour afterward confirmed an excellent gastrointestinal resorption of the drug in this group of patients with coronary artery disease who were fasting while awaiting an angioplasty procedure. Second, compliance could have been poor. Aggregation tests in one participating clinic showed that a 90% reduction of platelet aggregation via the TXA2 pathway was achieved in the treated group throughout the entire study. This indicated that patients were taking their medication and that the.drug was pharmacologically active. Third, it might be hypothesized that this substantial reduction in the aggregatory response of the platelet is still insufficient to prevent a substantial release of other factors involved in the initiation of the proliferative response.'340-42 In a recently published study, it was shown that GR32191 had no effect on primary aggregation induced by ADP, adrenaline, or platelet aggregating factor.43 In the present study, GR32191 was found to inhibit only 70% of the total platelet deposition on deendothelialized rabbit aorta using`'In-labeled human platelets from whole blood. 43 This was similar to the maximum inhibition achieved with prostacyclin and aspirin. Because several clinical trials with aspirin after balloon angioplasty have failed to prove a beneficial effect on restenosis,32A4-46 it might be retrospectively inferred that a similar level of platelet inhibition would also fail to alter the restenosis rate. Furthermore, the magnitude of TXA2-receptor blockade needed after balloon-induced vascular damage is not known. For example, a substantial increase in plasma levels of TXA2 metabolite 11-dehydro-thromboxane B2 from less than 50 to 174 pg/ml has been measured in the great cardiac vein after angioplasty of the left anterior descending coronary artery, despite pretreatment with aspirin. 47 One could question whether TXA2-receptor blockade is effective in the face of such an increase, although it has been demonstrated that GR32191 can achieve a more-than-100-fold displacement to the right of the platelet aggregation concentration-effect curve for U-46619 in healthy subjects. 36 More recently, it has been advocated that inhibition of platelet adhesion is a more efficient means to prevent subsequent aggregation of platelets. [48] [49] [50] [51] However, it can be argued that complete inhibition of adhesion will cause untoward bleeding effects. CUM % 1001 Finally, the pivotal role of the platelet in the initiation of the restenosis process might have been overestimated,52 and antiplatelet therapy as the sole modality of treatment may be intrinsically insufficient to control the restenosis phenomenon.
